You are here

Home ยป Company Details

CALISTA THERAPEUTICS INC

Company Information
Address
32 RIVERSIDE DR
LINCOLN, RI 02865-1511
United States
Information

UEI: E61VUUWBMTB7

# of Employees: 1
Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No

Award Charts




Award Listing

  • Record 1 TO 3

  1. Development of a selective PI3K-Akt-activating neurotrophic small molecule drug, MT-002, for the healing of corneal wounds in Neurotrophic Keratitis.

    Amount: $247,998.00

    Calista is developing topical MT-002, a selective PI3K-Akt activator that safely restores normal wound healing in a clinically predictive animal model of Neurotrophic Keratitis (NK). NK causes progres ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health

  2. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    Amount: $224,550.00

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold sta ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health

  3. An Automated Platform for High-throughput Network Electrophysiology

    Amount: $224,993.00

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cy ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government